Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells

Anticancer Research

Volumn 26, Issue 5 A, 2006, Pages 3265-3273

  Shrikhande, Shailesh V ^a,b   Kleeff, Jörg ^a   Kayed, Hany ^a   Keleg, Shereen ^a   Reiser, Carolin ^a   Giese, Thomas ^a   Büchler, Markus W ^a   Esposito, Irene ^a   Friess, Helmut ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

Apoptosis; Chemotherapy; Gene silencing; Pancreatic cancer; Pancreatic surgery; X linked inhibitor of apoptosis (XIAP)

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GEMCITABINE; MESSENGER RNA; OLIGOPEPTIDE; SMALL INTERFERING RNA; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE SILENCING; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 33750690650     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Warshaw AL and Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med 526: 455-465, 1992.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
3. Kindler HL: Front-line therapy of advanced pancreatic cancer. Semin Oncol 32: 33-36, 2005.
4. Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, Schmid RM and Buchler MW: bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 43: 414-421, 1998.
5. Friess H, Lu Z, Andren-Sandberg A, Berberat P, Zimmermann A, Adler G, Schmid R and Buchler MW: Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann Surg 228: 780-787, 1998.
6. Graber HU, Friess H, Zimmermann A, Korc M, Adler G, Schmid R and Buchler MW: Bak expression and cell death occur in peritumorous tissue but not in pancreatic cancer cells. J Gastrointest Surg 3: 74-80; discussion 81, 1999.
7. Xu Z, Friess H, Solioz M, Aebi S, Korc M, Kleeff J and Buchler MW: Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer 94: 268-274, 2001.
8. Xu ZW, Friess H, Buchler MW and Solioz M: Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother Pharmacol 49: 504-510, 2002.
9. Bai J, Sui J, Demirjian A, Vollmer CM Jr, Marasco W and Callery MP: Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 65: 2344-2352, 2005.
10. Biliran H Jr, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, Bollig A, Sarkar FH and Liao JD: Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 11: 6075-6086, 2005.
11. Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Buchler MW, Giese NA and Friess H: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 24: 4421-4432, 2005.
12. Giroux V, Malicet C, Barthet M, Gironella M, Archange C, Dagorn JC, Vasseur S and Iovanna JL: p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res 12: 235-241, 2006.
13. Ozawa F, Friess H, Zimmermann A, Kleeff J and Buchler MW: Enhanced expression of Silencer of death domains (SODD/BAG-4) in pancreatic cancer. Biochem Biophys Res Commun 271: 409-413, 2000.
14. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
15. Huang Q, Deveraux QL, Maeda S, Stennicke HR, Hammock BD and Reed JC: Cloning and characterization of an inhibitor of apoptosis protein (IAP) from Bombyx mori. Biochim Biophys Acta 1499: 191-198, 2001.
16. Hofmann HS, Simm A, Hammer A, Silber RE and Bartling B: Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J Cancer Res Clin Oncol 128: 554-560, 2002.
17. Ferreira CG, van der Valk P, Span SW, Jonker JM, Postmus PE, Kruyt FA and Giaccone G: Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann Oncol 12: 799-805, 2001.
18. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M and Reed JC: Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6: 1796-1803, 2000.
19. Bilim V, Kasahara T, Hara N, Takahashi K and Tomita Y: Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer 103: 29-37, 2003.
20. Fulda S, Meyer E and Debatin KM: Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21: 2283-2294, 2002.
21. Holcik M, Gordon BW and Korneluk RG: The internal ribosome entry site-mediated translation of antiapoptotic protein XIAP is modulated by the heterogeneous nuclear ribonucleoproteins C1 and C2. Mol Cell Biol 23: 280-288, 2003.
22. Sasaki H, Sheng Y, Kotsuji F and Tsang BK: Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 60: 5659-5666, 2000.
23. Yang L, Cao Z, Yan H and Wood WC: Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 63: 6815-6824, 2003.
24. Guo J, Kleeff J, Li J, Ding J, Hammer J, Zhao Y, Giese T, Korc M, Buchler MW and Friess H: Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene 23: 71-81, 2004.
25. Kayed H, Kleeff J, Keleg S, Guo J, Ketterer K, Berberat PO, Giese N, Esposito I, Giese T, Buchler MW and Friess H: Indian hedgehog signaling pathway: expression and regulation in pancreatic cancer. Int J Cancer 110: 668-676, 2004.
26. Strasser A, O'Connor L and Dixit VM: Apoptosis signaling. Annu Rev Biochem 69: 217-245, 2000.
27. Cryns V and Yuan J: Proteases to die for. Genes Dev 12: 1551-1570, 1998.
28. Thornberry NA and Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316, 1998.
29. Mohapatra S, Chu B, Zhao X and Pledger WJ: Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res 65: 7717-7723, 2005.
30. Vaux DL and Silke J: Mammalian mitochondrial LAP binding proteins. Biochem Biophys Res Commun 304: 499-504, 2003.
31. Nomura T, Yamasaki M, Nomura Y and Mimata H: Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 14: 993-997, 2005.
32. Trauzold A, Schmiedel S, Roder C, Tams C, Christgen M, Oestern S, Arlt A, Westphal S, Kapischke M, Ungefroren H and Kalthoff H: Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer 89: 1714-1721, 2003.
33. Gerhard MC, Schmid RM and Hacker G: Analysis of the cytochrome c-dependent apoptosis apparatus in cells from human pancreatic carcinoma. Br J Cancer 86: 893-898, 2002.
34. Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC and Glinsky GV: Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res 65: 2378-2386, 2005.
35. Ko AH and Tempero MA: Treatment of metastatic pancreatic cancer. J Natl Compr Cane Netw 3: 627-636, 2005.
36. Petrin D, Baker A, Coupland SG, Liston P, Narang M, Damji K, Leonard B, Chiodo VA, Timmers A, Hauswirth W, Korneluk RG and Tsilfidis C: Structural and functional protection of photoreceptors from MNU-induced retinal degeneration by the X-linked inhibitor of apoptosis. Invest Ophthalmol Vis Sci 44: 2757-2763, 2003.
37. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD and LaCasse EC: Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 9: 2826-2836, 2003.
38. Cao C, Mu Y, Hallahan DE and Lu B: XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23: 7047-7052, 2004.
39. Perrelet D, Perrin FE, Liston P, Korneluk RG, MacKenzie A, Ferrer-Alcon M and Kato AC: Motoneuron resistance to apoptotic cell death in vivo correlates with the ratio between X-linked inhibitor of apoptosis proteins (XIAPs) and its inhibitor, XIAP-associated factor 1. J Neurosci 24: 3777-3785, 2004.
40. McNeish IA, Bell S, McKay T, Tenev T, Marani M and Lemoine NR: Expression of Smac/DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9-mediated pathway. Exp Cell Res 286: 186-198, 2003.
41. Vogler M, Giagkousiklidis S, Genze F, Gschwend JE, Debatin KM and Fulda S: Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. Oncogene 24: 7190-7202, 2005.
42. Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL, Ding H, Elmore SW, Meadows RP, Olejniczak ET, Oleksijew A, Oltersdorf T, Rosenberg SH, Shoemaker AR, Tomaselli KJ, Zou H and Fesik SW: Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 47: 4417-4426, 2004.
43. Lampiasi N, Fodera D, D'Alessandro N, Cusimano A, Azzolina A, Tripodo C, Florena AM, Minervini MI, Notarbartolo M, Montalto G and Cervello M: The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int J Mol Med 17: 245-252, 2006.
44. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE and Price JE: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11: 7490-7498, 2005.
45. Lacasse EC, Kandimalla ER, Winocour P, Sullivan T, Agrawal S, Gillard JW and Durkin J: Application of XIAP Antisense to Cancer and Other Proliferative Disorders: Development of AEG35156/GEM(R)640. Ann NY Acad Sci 1058: 215-234, 2005.